Rotavirus Vaccine Effectiveness and Case-control Study on Risk Factors for Breakthrough Infections in Germany, 2010-2011

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages e82-e89

  Adlhoch, Cornelia ^a   Hoehne, Marina ^a   Littmann, Martina ^a   Marques, Andreas Mas ^a   Lerche, Almuth ^a   Dehnert, Manuel ^a   Eckmanns, Tim ^a   Wichmann, Ole ^a   Koch, Judith ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Breakthrough infection; Breastfeeding; Case control study; GP typing; Rotavirus vaccine; Vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; GENOTYPE; GERMANY; HOSPITALIZATION; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SCREENING; VACCINATION;

BREAST FEEDING; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FECES; FEMALE; GENOTYPE; GERMANY; HUMANS; INFANT; MALE; MASS VACCINATION; REGRESSION ANALYSIS; RISK FACTORS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84873043137     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182720b71     Document Type: Article

References (49)

1. Tate JE, Burton AH, Boschi-Pinto C, et al.WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136-141
2. Iturriza-Gomara M, Dallman T, Banyai K, et al. Rotavirus surveillance in europe, 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological data. J Infect Dis. 2009;200(suppl 1):S215-S221
3. Iturriza-Gómara M, Dallman T, Bányai K, et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect. 2011;139:895-909
4. Iturriza-Gòmara M, Anderton E, Kang G, et al. Evidence for genetic linkage between the gene segments encoding NSP4 and VP6 proteins in common and reassortant human rotavirus strains. J Clin Microbiol. 2003;41:3566-3573
5. Krause G, Altmann D, Faensen D, et al. SurvNet electronic surveillance system for infectious disease outbreaks, Germany. Emerging Infect Dis. 2007;13:1548-1555
6. Koch J, Wiese-Posselt M. Epidemiology of rotavirus infections in children less than 5 years of age: Germany, 2001-2008. Pediatr Infect Dis J. 2011;30:112-117
7. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al.Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11-22
8. Vesikari T, Matson DO, Dennehy P, et al.Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33
9. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009;301:2243-2251
10. De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J. 2004;23(10 suppl):S179-S182
11. Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J. 2006;25(suppl 1):S42-S47
12. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937-943
13. Itzler R, Koch G, Matson DO, et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatr. 2010;10:42
14. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J. 2011;30(suppl 1):S56-S60
15. Paulke-Korinek M, Rendi-Wagner P, Kundi M, et al. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J. 2010;29:319-323
16. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine. 2010;28:7507-7513
17. Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(suppl 1):S25-S29
18. Statistisches Bundesamt (Federal Health Monitoring). German Population (Age distribution) 2010 Available at: https://www-genesis.destatis.de/genesis/online Accessed May 2012
19. Poggensee G, Benzler J, Eckmanns T, et al.und die Mitarbeiter der Abteilung für Infektionsepidemiologie. On the 2007 edition of case definitions for the surveillance of notifiable infectious diseases in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;49:1189-1194
20. Faensen D, Claus H, Benzler J, et al. SurvNet@RKI-a multistate electronic reporting system for communicable diseases. Euro Surveill. 2006;11:100-103
21. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259-267
22. Mas Marques A, Diedrich S, Huth C, et al. Group A rotavirus genotypes in Germany during 2005/2006. Arch Virol. 2007;152:1743-1749
23. EuroRotaNet. European rotavirus detection and characterization methods v4. Available at: http://www.eurorota.net/docs.php Accessed May 2012
24. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22:742-746
25. World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. 2008 WHO/IVB/08.16. Geneva, Switzerland World Health Organization
26. Snelling TL, Andrews RM, Kirkwood CD, et al. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis. 2011;52:191-199
27. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125:e199-e207
28. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010;340:c2825
29. Linhares AC, Velázquez FR, Pérez-Schael I, et al.Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1181-1189
30. Dudareva-Vizule S, Koch J, An der Heiden M, et al. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother. 2012;8. [E-pub ahead of print]
31. Lange C, Schenk L, Bergmann R. Distribution, duration and temporal trend of breastfeeding in Germany. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50:624-633
32. Patel M, Shane AL, Parashar UD, et al. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200(suppl 1):S39-S48
33. Moon SS, Wang Y, Shane AL, et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J. 2010;29:919-923
34. Chan J, Nirwati H, Triasih R, et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine. 2011;29:1242-1247
35. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis. 1996;174(suppl 1):S107-S111
36. Vesikari T, Ruuska T, Bogaerts H, et al. Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr Infect Dis. 1985;4:622-625
37. Vesikari T, Ruuska T, Delem A, et al. Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months. Acta Paediatr Scand. 1986;75:573-578
38. Goveia MG, DiNubile MJ, Dallas MJ, et al.REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J. 2008;27:656-658
39. Dennehy PH, Brady RC, Halperin SA, et al.North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J. 2005;24:481-488
40. Vesikari T, Prymula R, Schuster V, et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J. 2012;31:509-513
41. Tompson M, LeVan Fram J, Eastman A, et al. Exclusive breastfeeding is best in all cases. Bull World Health Org. 2002;80:605
42. Reves RR, Morrow AL, Bartlett AV 3rd, et al. Child day care increases the risk of clinic visits for acute diarrhea and diarrhea due to rotavirus. Am J Epidemiol. 1993;137:97-107
43. Menon S, Santosham M, Reid R, et al. Rotavirus diarrhoea in Apache children: a case-control study. Int J Epidemiol. 1990;19:715-721
44. Louhiala PJ, Jaakkola N, Ruotsalainen R, et al. Day-care centers and diarrhea: a public health perspective. J Pediatr. 1997;131:476-479
45. Bartlett AV, Moore M, Gary GW, et al. Diarrheal illness among infants and toddlers in day care centers. II. Comparison with day care homes and households. J Pediatr. 1985;107:503-509
46. Sobel J, Gomes TA, Ramos RT, et al. Pathogen-specific risk factors and protective factors for acute diarrheal illness in children aged 12-59 months in São Paulo, Brazil. Clin Infect Dis. 2004;38:1545-1551
47. de Wit MA, Koopmans MP, van Duynhoven YT. Risk factors for norovirus, Sapporo-like virus, and group A rotavirus gastroenteritis. Emerging Infect Dis. 2003;9:1563-1570
48. Sethi D, Cumberland P, Hudson MJ, et al. A study of infectious intestinal disease in England: risk factors associated with group A rotavirus in children. Epidemiol Infect. 2001;126:63-70
49. Gurgel RQ, Cuevas LE, Vieira SC, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerging Infect Dis. 2007;13:1571-1573